{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:26:32Z","timestamp":1785893192173,"version":"3.56.0"},"reference-count":21,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T00:00:00Z","timestamp":1474588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2016,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Accurate determination of recipient cytomegalovirus (<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>) serostatus before allogeneic hematopoietic stem cell transplantation (<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>) is critical, as it is the most important predictor of post\u2010transplant <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> infection and remains associated with non\u2010relapse mortality. The purpose of this study was to assess a recipient dual\u2010testing strategy before <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> serologic testing was performed before allogeneic <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> using 2 different assays: reference laboratory (<jats:styled-content style=\"fixed-case\">RL<\/jats:styled-content>) and American Red Cross (<jats:styled-content style=\"fixed-case\">ARC<\/jats:styled-content>). In all cases, blood samples were obtained for <jats:styled-content style=\"fixed-case\">RL<\/jats:styled-content> testing either before <jats:styled-content style=\"fixed-case\">ARC<\/jats:styled-content> testing (median 130 days before <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> [range 12\u20132594]) or at the same time (median 25 days before <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> [range 8\u2013129]). The results of serologic testing were correlated with <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> viremia post <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 287 recipients evaluated, 76 (26.5%) had discordant results, of which 74 (97.4%) tested <jats:styled-content style=\"fixed-case\">RL<\/jats:styled-content>\u2212\/<jats:styled-content style=\"fixed-case\">ARC<\/jats:styled-content>+. Ten had <jats:styled-content style=\"fixed-case\">RL<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ARC<\/jats:styled-content> testing performed on simultaneously obtained samples, 3 of which (30%) were discordant (3 [100%] <jats:styled-content style=\"fixed-case\">RL<\/jats:styled-content>\u2212\/<jats:styled-content style=\"fixed-case\">ARC<\/jats:styled-content>+). Acute myeloid leukemia and receipt of blood product transfusion in the interval between testing were associated with <jats:styled-content style=\"fixed-case\">RL<\/jats:styled-content>\u2212\/<jats:styled-content style=\"fixed-case\">ARC<\/jats:styled-content>+ discordance. Correlation with viremia after <jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> suggested that <jats:styled-content style=\"fixed-case\">RL<\/jats:styled-content>\u2212\/<jats:styled-content style=\"fixed-case\">ARC<\/jats:styled-content>+ discordance was caused by detection of anti\u2010<jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> immunoglobulin transferred in transfused blood products and reduced specificity of the <jats:styled-content style=\"fixed-case\">ARC<\/jats:styled-content> assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content>\u2010seronegative hematopoietic stem cell transplant recipients may be misclassified as seropositive if testing is performed after receipt of blood products or when using assays optimized for sensitivity at the expense of specificity. This misclassification may negatively affect post\u2010<jats:styled-content style=\"fixed-case\">HSCT<\/jats:styled-content> outcomes for individual patients and studies that rely on accurate <jats:styled-content style=\"fixed-case\">CMV<\/jats:styled-content> serology reporting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tid.12591","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T08:09:47Z","timestamp":1470730187000},"page":"809-814","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of a cytomegalovirus serology dual\u2010testing strategy in hematopoietic stem cell transplant recipients"],"prefix":"10.1111","volume":"18","author":[{"given":"D.A.","family":"Perry","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Oregon Health and Science University Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hakki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Oregon Health and Science University Portland Oregon USA"},{"name":"Division of Infectious Diseases Oregon Health and Science University Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,23]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.89"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-499830"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00504.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3616"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.02.008"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu364"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12264"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705090"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/320898"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03203.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199803150-00001"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.07.015"},{"issue":"10","key":"e_1_2_6_14_1","first-page":"1","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"49","author":"Centers for Disease Control and Prevention (CDC), Infectious Disease Society of America, American Society of Blood and Marrow Transplant","year":"2000","journal-title":"MMWR Morbid Mortal Weekly Rep"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.026484"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.7.2183"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2003.00312.x"},{"issue":"5","key":"e_1_2_6_18_1","first-page":"634","article-title":"The half\u2010lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious S","year":"1988","journal-title":"J Lab Clin Med"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1182\/blood.V86.9.3598.bloodjournal8693598","article-title":"Comparison of filtered blood (FB) to seronegative blood products (SB) for prevention of cytomegalovirus (CMV) infection after marrow transplant","volume":"86","author":"Bowden R","year":"1995","journal-title":"Blood"},{"issue":"1","key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/blood.V78.1.246.246","article-title":"Use of leukocyte\u2010depleted platelets and cytomegalovirus\u2010seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant","volume":"78","author":"Bowden RA","year":"1991","journal-title":"Blood"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.013"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000085"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftid.12591","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.12591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T02:27:38Z","timestamp":1696040858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.12591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,23]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["10.1111\/tid.12591"],"URL":"https:\/\/doi.org\/10.1111\/tid.12591","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,23]]}}}